MB-106
Relapsed/Refractory B-cell NHL & CLL
Phase 1/2Active
Key Facts
About Mustang Bio
Mustang Bio is a clinical-stage biopharmaceutical company dedicated to translating breakthroughs in cell therapy into potential cures for cancers with high unmet medical need. Its strategy centers on a capital-efficient model of in-licensing first-in-class candidates, primarily CAR T therapies, from top-tier research institutions like City of Hope. The company has advanced a pipeline of CAR T programs into clinical trials for aggressive brain tumors and hematologic malignancies, with recent Phase 1 data showing promising survival signals. A key pillar of its approach is developing advanced, controlled manufacturing processes to overcome the scalability challenges inherent in cell therapy.
View full company profile